Intelence (Etravirine, TMC125)
| Brand Name: |
Intelence |
| Generic Name: |
Etravirine, TMC125 |
| Adult Single Dose: |
Two 100-mg tablets twice a day |
| Food & Liquid Restrictions: |
Take after a meal
|
| Drug Class: |
NNRTI |
|
|
|
 |
| Click here for a summary of the essential details on Intelence (etravirine, TMC125) from Cal Cohen, M.D. |
|
The Basics
- An Overview of Intelence (TMC125, Etravirine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- HIV/AIDS Update -- New Intelence Labeling: Severe Skin and Hypersensitivity Reactions (August 2009)
Important drug warning.
To read PDF, click here
From Tibotec Therapeutics
- Etravirine (Intelence) (August 23, 2009)
To read PDF, click here
From AIDS InfoNet
- Patient Information About Intelence (TMC125, Etravirine) (PDF) (August 2009)
From Tibotec Therapeutics
- Intelence (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- News Analysis: U.S. Approval of Intelence (Etravirine) (January 25, 2008)
An interview with Cal Cohen, M.D., M.S.
From The Body
- Project Inform Welcomes Approval and Pricing of Intelence, Calls for Further Research (January 23, 2008)
From Project Inform
- Intelence (TMC125, Etravirine) Approved in United States (January 19, 2008)
From U.S. Food and Drug Administration
- Intelence (TMC125, Etravirine) Patient Product Information (PDF) (January 2008)
From Tibotec Therapeutics
- Intelence (Etravirine) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
News & Research
- Information for Health Care Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Health Care Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC) (November 17, 2009)
From U.S. Food and Drug Administration
- Tibotec, FDA Update Warning Label on HIV Drug's Risk of Severe Skin Reaction (August 27, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- New FDA Report Suggests Possible Link Between Intelence and Joint Problems (September 8, 2008)
From Associated Press
- AAHIVM Encouraged by TMC125 Approval (January 22, 2008)
New HIV medication could offer more options for treatment-experienced patients.
From American Academy of HIV Medicine
- Fair Pricing Coalition Lauds Pricing of New Tibotec Drug (January 21, 2008)
From Fair Pricing Coalition
- FDA Receives New Drug Application for TMC125 (Etravirine) (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
- MK-0518 Plus Etravirine? No Problem! (January 5, 2007)
From Project Inform
- Tibotec Announces Expanded Access Programme for New NNRTI TMC125 (September 26, 2006)
From aidsmap.com
- Tibotec Pharmaceuticals Ltd. Announces Expanded Access Program for Its Investigational Agent TMC125 (September 25, 2006)
Program will provide early access for eligible HIV-1-infected patients who have limited treatment options.
From Tibotec Pharmaceuticals Ltd.
- AIDS Activists Urge Tibotec to Expand Access to TMC125, Show Compassion for HIV Salvage Patients (March 8, 2006)
From Salvage Therapies
|
|
Advertisement
|
E-Mail
Glossary
Share
